Julie Rubinstein serves as the President and Chief Operating Officer at Adaptive Biotechnologies Corp, a pioneering company in the field of immune-driven medicine. With a robust background in the life sciences and healthcare industries, Rubinstein has been instrumental in steering Adaptive Biotechnologies towards significant growth and innovation. Before joining Adaptive Biotechnologies, she held various leadership positions, including roles at Seattle Genetics and Amgen, where she honed her skills in operational management and strategic planning. Her expertise spans across multiple areas, including oncology, immunology, and molecular diagnostics, making her a valuable asset to the company. At Adaptive Biotechnologies, Rubinstein oversees the company's day-to-day operations and plays a crucial role in shaping its strategic direction. Under her leadership, the company has made significant strides in developing advanced diagnostic tools and therapies that leverage the power of the immune system. One of her notable achievements includes the successful launch of clonoSEQ, a next-generation sequencing-based minimal residual disease (MRD) test that has revolutionized the monitoring and management of certain cancers. Rubinstein's commitment to advancing personalized medicine is evident in her efforts to foster collaborations with leading academic institutions and industry partners, further enhancing Adaptive Biotechnologies' position at the forefront of immune-driven medicine. Rubinstein's leadership style is characterized by her ability to inspire and mobilize teams towards a common goal. Her strategic vision and operational acumen have been pivotal in navigating the complex landscape of biotechnology and healthcare. As Adaptive Biotechnologies continues to expand its portfolio and explore new frontiers in immune-driven medicine, Rubinstein's role as President and COO remains central to the company's mission of transforming the lives of patients worldwide.